Loriot Y - Search Results

1

The Role of CT in the Staging and Follow-Up of Testicular Tumors: Baseline, Recurrence and Pitfalls.

Pierre T, Selhane F, Zareski E, Garcia C, Fizazi K, Loriot Y, Patrikidou A, Naoun N, Bernard-Tessier A, Baumert H, Lebacle C, Blanchard P, Rocher L, Balleyguier C. Pierre T, et al. Among authors: loriot y. Cancers (Basel). 2022 Aug 17;14(16):3965. doi: 10.3390/cancers14163965. Cancers (Basel). 2022. PMID: 36010958 Free PMC article. Review.

2

[Management of localized germ-cell tumours of the testis].

Loriot Y, Fizazi K. Loriot Y, et al. Rev Prat. 2007 Feb 28;57(4):379-84. Rev Prat. 2007. PMID: 17455739 Review. French.

3

[Management of clinical stage I testicular germ cell tumours].

Loriot Y, Fizazi K. Loriot Y, et al. Bull Cancer. 2007 May;94(5):439-48. Bull Cancer. 2007. PMID: 17535781 Review. French.

4

Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Fizazi K. Loriot Y, et al. Ann Oncol. 2009 Apr;20(4):703-8. doi: 10.1093/annonc/mdn694. Epub 2009 Jan 29. Ann Oncol. 2009. PMID: 19179557 Free article.

5

[New drugs in metastatic castration-resistant prostate cancer].

Albiges L, Loriot Y, Gross-Goupil M, de La Motte Rouge T, Blesius A, Escudier B, Massard C, Fizazi K. Albiges L, et al. Among authors: loriot y. Bull Cancer. 2010 Jan;97(1):149-59. doi: 10.1684/bdc.2009.1023. Bull Cancer. 2010. PMID: 20022854 French.

6

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Chauchereau A, Fizazi K. Loriot Y, et al. Eur J Cancer. 2010 Jul;46(10):1770-2. doi: 10.1016/j.ejca.2010.04.010. Epub 2010 May 17. Eur J Cancer. 2010. PMID: 20483588

7

How to select targeted therapy in renal cell cancer.

Escudier B, Albiges L, Blesius A, Loriot Y, Massard C, Fizazi K. Escudier B, et al. Among authors: loriot y. Ann Oncol. 2010 Oct;21 Suppl 7:vii59-62. doi: 10.1093/annonc/mdq371. Ann Oncol. 2010. PMID: 20943644 Free article. Review.

8

Carcinomas of an unknown primary origin--diagnosis and treatment.

Massard C, Loriot Y, Fizazi K. Massard C, et al. Among authors: loriot y. Nat Rev Clin Oncol. 2011 Nov 1;8(12):701-10. doi: 10.1038/nrclinonc.2011.158. Nat Rev Clin Oncol. 2011. PMID: 22048624 Review.

9

Recent developments in treatments targeting castration-resistant prostate cancer bone metastases.

Loriot Y, Massard C, Fizazi K. Loriot Y, et al. Ann Oncol. 2012 May;23(5):1085-1094. doi: 10.1093/annonc/mdr573. Epub 2012 Jan 20. Ann Oncol. 2012. PMID: 22267211 Free article. Review.

10

Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen.

Edeline J, Loriot Y, Culine S, Massard C, Albiges L, Blesius A, Escudier B, Fizazi K. Edeline J, et al. Among authors: loriot y. Eur J Cancer. 2012 May;48(8):1141-6. doi: 10.1016/j.ejca.2012.01.022. Epub 2012 Feb 22. Eur J Cancer. 2012. PMID: 22364733

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

307 results

Search Page

Filters